Rapid7, Inc. (NASDAQ: RPD), a leader in extended risk and threat detection, today announced that it has been recognized as ‘Security Vendor of the Year’ at the CRN Channel Awards 2024. One of the ...
Obtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium (186Re) Obisbemeda for the treatment of patients with leptomeningeal metastases (LM) Presented positive ReS ...